Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Current Development Status and Availability Outlook Retatrutide has no MHRA or EMA marketing authorisation and is not available outside clinical trials
Ajanta Pharma and Emcure have already announced partnerships with Biocon and Novo Nordisk to commercialise semaglutide brands in India and international markets
Researchers have noted that GLP-1 drugs seem to reduce the release of dopamine when consuming alcohol, potentially making drinking less rewarding and reducing the urge to continue drinking
Research over nearly a decade has shown that the GLP-1 drug semaglutide can lead to remarkable impacts on cardiovascular function in patients with Type 2 diabetes and/or overweight and obesity
Findings published in a preprint from a phase I clinical trial on the GLP1glucagon receptor co-agonist NN1177 in adults with overweight or obesity have raised problems with deterioration of glucose tolerance and other safety concerns, despite inducing weight loss, which illustrates the difficulties in getting the agonist balance right during the preclinical development of co-agonist therapies 6,7
Request a prescription transfer and our pharmacy team will help coordinate the next step
